NTLA FY 2022 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$52M+57.7% YoY

Gross Profit

$45M85.5% margin

Operating Income

-$458M-879.0% margin

Net Income

-$474M-909.8% margin

EPS (Diluted)

$-6.16

Cash Flow

Operating Cash Flow

-$333M

Free Cash Flow

-$392M

Stock-Based Comp.

$91M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$285M

Stockholders' Equity

$1.2B

Cash & Equivalents

$524M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$52M	$33M	+57.7%
Gross Profit	$45M	$26M	+70.3%
Operating Income	-$458M	-$268M	-71.1%
Net Income	-$474M	-$268M	-77.0%